^
    3d
    A Case of Advanced Gastric Cancer with Postoperative Multiple Metastasis, That Obtained Long-Term Survival after Multimodal Therapy (PubMed, Gan To Kagaku Ryoho)
    Because of HER2 negative, 2 courses of ramucirumab plus paclitaxel was administered, but lung metastasis, increased liver metastasis, and ascites were detected...Nivolumab treatment was continued, and there has been no further disease progression at 83 months post-surgery. This case shows that disease control was achieved with nivolumab for liver, lung, and lymph node metastases following gastric cancer surgery, and long-term survival was attained with multimodal therapy.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • paclitaxel • Cyramza (ramucirumab) • Teysuno (gimeracil/oteracil/tegafur)
    4d
    A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (clinicaltrials.gov)
    P3, N=545, Active, not recruiting, Eli Lilly and Company | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • erlotinib • gefitinib • Cyramza (ramucirumab) • simmitinib (SYHA1817)
    5d
    Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC (clinicaltrials.gov)
    P2, N=36, Active, not recruiting, Fox Chase Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Opdivo (nivolumab) • Cyramza (ramucirumab)
    7d
    Outcomes of Ramucirumab Monotherapy for Advanced Gastric Cancer in a Multi-institutional Cohort Study in Japan. (PubMed, J Gastrointest Cancer)
    Ramucirumab monotherapy is selected for patients with poor general condition, but it is suggested to have a poor prognosis, particularly in cases with liver metastases.
    Retrospective data • Journal • PD(L)-1 Biomarker
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CA 19-9 (Cancer antigen 19-9)
    |
    Opdivo (nivolumab) • Cyramza (ramucirumab)
    12d
    Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy (clinicaltrials.gov)
    P2, N=126, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    paclitaxel • Cyramza (ramucirumab) • irinotecan • Lonsurf (trifluridine/tipiracil) • bemarituzumab (AMG 552)
    21d
    Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=43, Active, not recruiting, Washington University School of Medicine | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Cyramza (ramucirumab)
    28d
    Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer (clinicaltrials.gov)
    P2, N=100, Recruiting, Universitaire Ziekenhuizen KU Leuven | Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2029 --> Dec 2029
    Enrollment open • Trial primary completion date
    |
    paclitaxel • Cyramza (ramucirumab) • Vyloy (zolbetuximab-clzb)
    1m
    ALTAIR: A Platform Study in Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1/2, N=152, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting | Trial completion date: Oct 2028 --> Feb 2029 | Trial primary completion date: Oct 2028 --> Feb 2029
    Enrollment open • Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • Cyramza (ramucirumab) • pemetrexed • rilvegostomig (AZD2936)
    1m
    MORPHEUS-EC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (clinicaltrials.gov)
    P1/2, N=214, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | N=410 --> 214
    Trial completion • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    HER-2 negative • HER-2 expression
    |
    cisplatin • Tecentriq (atezolizumab) • paclitaxel • 5-fluorouracil • Cotellic (cobimetinib) • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium • tiragolumab (RG6058) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide)
    1m
    Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) (clinicaltrials.gov)
    P1/2, N=210, Recruiting, Merck Sharp & Dohme LLC | N=90 --> 210
    Enrollment change
    |
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    Keytruda (pembrolizumab) • paclitaxel • Cyramza (ramucirumab) • patritumab deruxtecan (U3-1402) • Jiataile (sacituzumab tirumotecan)
    1m
    CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor (clinicaltrials.gov)
    P1/2, N=30, Active, not recruiting, Eli Lilly and Company | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    cyclophosphamide • Cyramza (ramucirumab) • vinorelbine tartrate
    1m
    Phase II study of FOLFIRI with low-dose irinotecan plus ramucirumab as second-line treatment in Japanese patients with metastatic colorectal cancer (study rindo). (PubMed, Jpn J Clin Oncol)
    FOLFIRI with low-dose irinotecan plus RAM is a feasible second-line treatment in Japanese patients with mCRC.
    P2 data • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    Avastin (bevacizumab) • 5-fluorouracil • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • levoleucovorin calcium